Premium
Seroresponses and safety of 13‐valent pneumococcal conjugate vaccination in kidney transplant recipients
Author(s) -
Dendle Claire,
Stuart Rhonda L.,
Polkinghorne Kevan R.,
Balloch Anne,
Kanellis John,
Ling Johnathan,
Kummrow Megan,
Moore Chelsea,
Thursky Karin,
Buttery Jim,
Mulholland Kim,
Gan PohYi,
Holdsworth Stephen,
Mulley William R.
Publication year - 2018
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12866
Subject(s) - medicine , vaccination , immunology , immunogenicity , pneumococcal vaccine , antibody , kidney transplantation , serotype , antibody titer , streptococcus pneumoniae , transplantation , titer , microbiology and biotechnology , biology , antibiotics
Abstract Background Conjugated pneumococcal vaccine is recommended for kidney transplant recipients, however, their immunogenicity and potential to trigger allograft rejection though generation of de novo anti‐human leukocyte antigen antibodies has not been well studied. Methods Clinically stable kidney transplant recipients participated in a prospective cohort study and received a single dose of 13‐valent conjugate pneumococcal vaccine. Anti‐pneumococcal IgG was measured for the 13 vaccine serotypes pre and post vaccination and functional anti‐pneumococcal IgG for 4 serotypes post vaccination. Anti‐human leukocyte antigen antibodies antibodies were measured before and after vaccination. Kidney transplant recipients were followed clinically for 12 months for episodes of allograft rejection or invasive pneumococcal disease. Results Forty‐five kidney transplant recipients participated. Median days between pre and post vaccination serology was 27 (range 21‐59). Post vaccination, there was a median 1.1 to 1.7‐fold increase in anti‐pneumococcal IgG antibody concentrations for all 13 serotypes. Kidney transplant recipients displayed a functional antibody titer ≥1:8 for a median of 3 of the 4 serotypes. Post vaccination, there were no de novo anti‐human leukocyte antigen antibodies, no episodes of biopsy proven rejection or invasive pneumococcal disease. Conclusion A single dose of 13‐valent conjugate pneumococcal vaccine elicits increased titers and breadth of functional anti‐pneumococcal antibodies in kidney transplant recipients without stimulating rejection or donor‐specific antibodies.